{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:41:09Z","timestamp":1793374869980,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12325-026-03518-2","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:42:47Z","timestamp":1772448167000},"page":"1369-1379","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Overcoming Hyperkalaemia as a Barrier to Achieving Optimal RAASi Therapy and Cardiorenal Protection in Individuals with Cardiorenal Disease: A Podcast Discussion"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8732-4088","authenticated-orcid":false,"given":"Andrew H.","family":"Frankel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Bramham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Chumber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Jane","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Fuat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Priestman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandie","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon G.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Wheatcroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"4S","key":"3518_CR1","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","journal-title":"Kidney Int"},{"issue":"36","key":"3518_CR2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"issue":"17","key":"3518_CR3","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):1757\u201380. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.011.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"3518_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012655","volume":"8","author":"C Linde","year":"2019","unstructured":"Linde C, Bakhai A, Furuland H, et al. Real-world associations of renin-angiotensin-aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom. J Am Heart Assoc. 2019;8(22):e012655. https:\/\/doi.org\/10.1161\/JAHA.119.012655.","journal-title":"J Am Heart Assoc"},{"key":"3518_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n189","volume":"372","author":"A Albasri","year":"2021","unstructured":"Albasri A, Hattle M, Koshiaris C, et al. Association between antihypertensive treatment and adverse events: systematic review and meta-analysis. BMJ. 2021;372:n189. https:\/\/doi.org\/10.1136\/bmj.n189.","journal-title":"BMJ"},{"key":"3518_CR6","unstructured":"Epstein M, Reaven NL, Funk SE, et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(11 Suppl):S212\u201320.\u00a0https:\/\/www.ajmc.com\/view\/a579_sep15_raasi_epstein_s212."},{"issue":"1","key":"3518_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-022-03054-5","volume":"24","author":"E Kanda","year":"2023","unstructured":"Kanda E, Rastogi A, Murohara T, et al. Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia. BMC Nephrol. 2023;24(1):18. https:\/\/doi.org\/10.1186\/s12882-022-03054-5.","journal-title":"BMC Nephrol"},{"issue":"8","key":"3518_CR8","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ejhf.1199","volume":"20","author":"M Trevisan","year":"2018","unstructured":"Trevisan M, de Deco P, Xu H, et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail. 2018;20(8):1217\u201326. https:\/\/doi.org\/10.1002\/ejhf.1199.","journal-title":"Eur J Heart Fail"},{"key":"3518_CR9","unstructured":"British Cardiovascular Society. CaReMe UK Guidelines and Resources. 2025. https:\/\/britishcardiovascularsociety.org.uk\/careme-resources\/. Accessed 1 Jun 2025."},{"issue":"9","key":"3518_CR10","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/ejhf.2612","volume":"24","author":"JO Burton","year":"2022","unstructured":"Burton JO, Coats AJS, Kovesdy CP, et al. An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum. Eur J Heart Fail. 2022;24(9):1467\u201377. https:\/\/doi.org\/10.1002\/ejhf.2612.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"3518_CR11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/ckj\/sfab243","volume":"15","author":"T Humphrey","year":"2022","unstructured":"Humphrey T, Davids MR, Chothia MY, et al. How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies. Clin Kidney J. 2022;15(4):727\u201337. https:\/\/doi.org\/10.1093\/ckj\/sfab243.","journal-title":"Clin Kidney J"},{"issue":"3","key":"3518_CR12","doi-asserted-by":"publisher","first-page":"264e9\u201324","DOI":"10.1016\/j.amjmed.2012.08.016","volume":"126","author":"Z Harel","year":"2013","unstructured":"Harel Z, Harel S, Shah PS, et al. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med. 2013;126(3):264e9-24. https:\/\/doi.org\/10.1016\/j.amjmed.2012.08.016.","journal-title":"Am J Med"},{"issue":"4","key":"3518_CR13","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.xkme.2020.04.007","volume":"2","author":"DJ Clegg","year":"2020","unstructured":"Clegg DJ, Headley SA, Germain MJ. Impact of dietary potassium restrictions in CKD on clinical outcomes: benefits of a plant-based diet. Kidney Med. 2020;2(4):476\u201387. https:\/\/doi.org\/10.1016\/j.xkme.2020.04.007.","journal-title":"Kidney Med"},{"issue":"2","key":"3518_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1155\/2015\/457431","volume":"22","author":"P Li","year":"2015","unstructured":"Li P, Boyd JM, Ghali WA, Stelfox HT. Stakeholder views regarding patient discharge from intensive care: suboptimal quality and opportunities for improvement. Can Respir J. 2015;22(2):109\u201318. https:\/\/doi.org\/10.1155\/2015\/457431.","journal-title":"Can Respir J"},{"issue":"1","key":"3518_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/jfmpc.jfmpc_837_19","volume":"9","author":"R Kuriakose","year":"2020","unstructured":"Kuriakose R, Aggarwal A, Sohi RK, et al. Patient safety in primary and outpatient health care. J Fam Med Prim Care. 2020;9(1):7\u201311. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_837_19.","journal-title":"J Fam Med Prim Care"},{"issue":"2","key":"3518_CR16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1177\/0272989x13508008","volume":"34","author":"JP Bynum","year":"2014","unstructured":"Bynum JP, Barre L, Reed C, Passow H. Participation of very old adults in health care decisions. Med Decis Mak. 2014;34(2):216\u201330. https:\/\/doi.org\/10.1177\/0272989x13508008.","journal-title":"Med Decis Mak"},{"issue":"2","key":"3518_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/biology11020179","volume":"11","author":"FQ Goh","year":"2022","unstructured":"Goh FQ, Kong WKF, Wong RCC, et al. Cognitive impairment in heart failure\u2014a review. Biol. 2022;11(2):179. https:\/\/doi.org\/10.3390\/biology11020179.","journal-title":"Biol"},{"issue":"9","key":"3518_CR18","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1111\/ene.15928","volume":"30","author":"M P\u00e9pin","year":"2023","unstructured":"P\u00e9pin M, Klimkowicz-Mrowiec A, Godefroy O, et al. Cognitive disorders in patients with chronic kidney disease: approaches to prevention and treatment. Eur J Neurol. 2023;30(9):2899\u2013911. https:\/\/doi.org\/10.1111\/ene.15928.","journal-title":"Eur J Neurol"},{"key":"3518_CR19","unstructured":"National Health Service England. Making every contact count (MECC). 2024. https:\/\/www.hee.nhs.uk\/our-work\/population-health\/our-resources-hub\/making-every-contact-count-mecc. Accessed 1 Jul 2024."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03518-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03518-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03518-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:14:06Z","timestamp":1775726046000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03518-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["3518"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03518-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrew H. Frankel prepared and delivered educational materials, attended advisory boards, and received research grants by Boehringer Ingelheim, Eli Lilly and Company, AstraZeneca, Bayer, and Menarini. Kate Bramham attended advisory boards for AstraZeneca, Maze, Alexion, GSK, and Bayer, and received honoraria from Alexion, AstraZeneca, GSK, Vertex Pharma, and Otsuka Pharmaceutical. Barbara Byrne received speaker fees and conference support from Servier, Novartis, Pfizer, and AstraZeneca. Geraldine Chiu and Laura Gray are employees of, and may hold stock in, AstraZeneca. Ruby Chumber received speaker and advisory board fees from AstraZeneca. Sarah Jane Davies received honorarium or support for speaking and attended meetings from Abbott, Amarin Corporation, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Dexcom, Eli Lilly and Company, Menarini, Novo Nordisk, and Roche. Ahmet Fuat received speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, and Vifor Pharma. Darren Green received speaker fees from AstraZeneca, Novartis, Boehringer Ingelheim, Eli Lilly and Company, and GSK. Darren Green holds collaborative working agreements with Novartis, Boehringer Ingelheim, and AstraZeneca, and received consultancy fees from AstraZeneca, GSK, and Bayer. William Priestman received honorarium from AstraZeneca. Mandie Welch received speaker fees from AstraZeneca, Novartis, Boehringer Ingelheim, and Abbott, and received advisory board fees from Pharmacosmos, AstraZeneca, and Boehringer Ingelheim. Simon G. Williams received speaker fees and honoraria for advisory work from Novartis, AstraZeneca, Bayer, and Vifor Pharma. Stephen Wheatcroft received speaker fees from Amarin Corporation, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly and Company, and Novo Nordisk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethics guidelines are not applicable to this article, as this commentary does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}